Is prescribing nitrofurantoin (Macrobid) appropriate for a female patient whose urine culture shows 10,000–49,000 CFU/mL coagulase‑negative Staphylococcus (not S. saprophyticus)?

Prescribing Macrobid for Low-Count Coagulase-Negative Staphylococcus (Non-Saprophyticus) is Problematic

Starting nitrofurantoin empirically for a urine culture showing 10,000-49,000 CFU/mL of coagulase-negative Staphylococcus (not S. saprophyticus) is questionable, as this likely represents contamination or asymptomatic bacteriuria rather than true infection, and nitrofurantoin's FDA-approved spectrum specifically includes only S. saprophyticus among coagulase-negative staphylococci.

Why This is Concerning

The Colony Count is Below Standard Thresholds

• Traditional diagnostic criteria require ≥10^5 CFU/mL for diagnosing UTI 1
• Your culture shows only 10^4-49,000 CFU/mL, which falls into a gray zone
• While some symptomatic women with true cystitis can have counts of 10^2-10^4 CFU/mL 2, this applies primarily to E. coli and S. saprophyticus, not other coagulase-negative staphylococci
• Coagulase-negative staphylococci (excluding S. saprophyticus) are frequent skin contaminants and their recovery at low counts strongly suggests contamination rather than infection 3

The Organism is Not in Nitrofurantoin's Primary Spectrum

The FDA label for Macrobid is explicit 4:

• Approved only for E. coli and S. saprophyticus causing acute uncomplicated cystitis
• While the label notes that "at least 90% of coagulase-negative staphylococci (including S. epidermidis)" have favorable MICs in vitro 4, this does not mean clinical efficacy has been established
• The FDA specifically states: "the efficacy of nitrofurantoin in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled trials" 4

IDSA Guidelines Don't Address This Scenario

The 2011 IDSA/ESMID guidelines 1 recommend nitrofurantoin as first-line therapy for acute uncomplicated cystitis, but:

• All efficacy data come from studies of E. coli and S. saprophyticus
• Clinical cure rates of 88-93% and bacterial cure rates of 86-92% 1 apply to these organisms only
• No guideline evidence supports treating other coagulase-negative staphylococci at low colony counts

What You Should Do Now

Assess Whether This is True Infection vs. Contamination

Key clinical features that suggest true UTI 2:

• Internal dysuria (not external)
• Frequency, urgency, small-volume voids
• Abrupt onset
• Suprapubic pain
• Pyuria present
• Hematuria (strongly suggests bacterial cystitis)

If symptoms are absent or minimal: This is likely asymptomatic bacteriuria or contamination, and treatment is not indicated 5

If True Symptomatic Infection is Present

You have three reasonable options:

1. Continue nitrofurantoin empirically (100 mg twice daily for 5-7 days 1, 6) and monitor clinical response closely

   • Rationale: In vitro susceptibility data suggest it may work 4
   • Risk: No proven clinical efficacy for this organism
   • If symptoms don't improve within 48-72 hours, switch antibiotics

2. Switch to trimethoprim-sulfamethoxazole (160/800 mg twice daily for 3 days 1)

   • Better established for broader range of uropathogens
   • Only use if local resistance rates <20% 1
   • More systemic distribution than nitrofurantoin

3. Switch to a first-generation cephalosporin (e.g., cephalexin 500 mg four times daily for 5-7 days 1, 6)

   • Excellent activity against staphylococci
   • Reasonable option when nitrofurantoin spectrum is uncertain

Critical Pitfall to Avoid

Do not assume all "coagulase-negative staph" are the same. S. saprophyticus causes true UTI in young women and responds to nitrofurantoin 1, 4. Other coagulase-negative staphylococci (S. epidermidis, S. hominis, etc.) are usually contaminants 7, 3, especially at low colony counts.

Bottom Line Algorithm

1. Reassess clinical symptoms → If absent/minimal, stop antibiotics (likely contamination/ASB)
2. If truly symptomatic with pyuria:
   • Continue nitrofurantoin for now BUT
   • Set 48-72 hour clinical checkpoint
   • If not improving, switch to TMP-SMX or cephalexin based on local resistance patterns
3. Consider repeat culture if symptoms persist despite therapy

The empiric choice of nitrofurantoin was reasonable before culture results, but now that you know the organism, close clinical follow-up is essential to ensure treatment success 4.